证券代码：600866 证券简称：星湖科技 公告编号：临 2025-037 诺的保证，具体内容详见公司于 2023 年 12 月 28 日在上海证券交易 所网站（www.sse.com.cn）披露的《关于持股 5%以上股东部分股份 质押的公告》（公告编号：临 2023-051）。根据信永中和会计师事务 所（特殊普通合伙）出具的《关于宁夏伊品生物科技股份有限公司 2024 年 度 及 累 积 承 诺 业 绩 实 现 情 况 的 审 核 报 告 》 （XYZH/2025GZAA1B0214 号），宁夏伊品生物科技股份有限公司 2022、 2023、2024 年度的业绩承诺已经实现，广新集团、伊品集团以及铁 小荣关于伊品生物 2022、2023、2024 年度的业绩承诺得到了有效履 行，截至 2024 年度无需对上市公司进行补偿。 广东肇庆星湖生物科技股份有限公司 关于持股 5%以上股东股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 截至本公告披露日，广东肇庆星湖生物科技股份有限公司（以 下简称 ...

Core Viewpoint - The company, Guangdong Zhaoqing Xinghuo Biotechnology Co., Ltd., anticipates a significant increase in net profit for the first half of 2025, projecting a rise of over 50% compared to the same period last year [2][4]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 790 million to 850 million yuan, an increase of 283.83 million to 343.83 million yuan, representing a year-on-year growth of 56.07% to 67.93% [2][4]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be between 760 million to 820 million yuan, an increase of 225.69 million to 285.69 million yuan, reflecting a year-on-year increase of 42.24% to 53.47% [2][4]. Group 2: Previous Year’s Performance - In the first half of 2024, the total profit was 648.20 million yuan, with a net profit attributable to shareholders of the parent company at 506.17 million yuan, and a net profit excluding non-recurring gains and losses at 534.31 million yuan [6]. Group 3: Reasons for Performance Change - The company achieved improved performance in the first half of 2025 through enhanced internal management and the implementation of "three precision management" initiatives, leading to increased efficiency in production and operations [8]. - Additionally, a decrease in the procurement costs of key raw materials contributed to the overall optimization of product costs, positively impacting profit growth [8]. Group 4: Shareholder Information - As of the announcement date, the major shareholder, Ningxia Yipin Investment Group Co., Ltd., and its associated party hold a total of 233,036,630 shares, accounting for 14.03% of the company's total share capital [11]. - The shareholder, Tie Xiaorong, has released a pledge on 57,043,761 shares, which is 94.52% of his pledged shares, representing 3.43% of the total share capital [11][12]. - After the release of the pledge, Tie Xiaorong has no pledged shares remaining, while the total pledged shares by him and his associates amount to 89,351,604 shares, which is 38.34% of their total holdings and 5.38% of the total share capital [12][14].

Group 1 - The company expects to achieve a net profit attributable to shareholders of the parent company for the first half of 2025 in the range of 790 million to 850 million yuan, representing an increase of 56.07% to 67.93% compared to the same period last year [1][2] - The estimated net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 760 million and 820 million yuan, which is an increase of 42.24% to 53.41% compared to the previous year [1][2] - The previous year's net profit attributable to shareholders of the parent company for the first half of 2024 was 506.17 million yuan, with a total profit of 648.20 million yuan [2] Group 2 - The company attributes the profit increase to improvements in production efficiency and a decrease in the procurement costs of major raw materials during the reporting period, leading to optimized overall product costs [2] - The earnings per share for the first half of 2024 was reported at 0.3047 yuan [2]

Core Viewpoint - The announcement details the release of share pledges by a major shareholder of Guangdong Zhaoqing Xinghuo Biotechnology Co., Ltd., indicating a positive development in the company's shareholder structure and financial commitments [1][2]. Shareholder Information - As of the announcement date, the major shareholder, Ningxia Yipin Investment Group Co., Ltd. and its concerted actor, Tie Xiaorong, collectively hold 233,036,630 shares, accounting for 14.03% of the total share capital of the company [1]. - Tie Xiaorong has released 57,043,761 shares from pledge, which represents 94.52% of his pledged shares and 3.43% of the company's total share capital [2]. Pledge Details - After the release of the pledge, Tie Xiaorong has no remaining pledged shares, while the total pledged shares by him and his concerted actors amount to 89,351,604 shares, which is 38.34% of their total holdings and 5.38% of the company's total share capital [1][2]. - The pledged shares were originally provided to Guangdong Guangxin Holdings Group Co., Ltd. as a guarantee for performance commitments [1]. Performance Commitments - The performance commitments for Ningxia Yipin Biotechnology Co., Ltd. for the years 2022, 2023, and 2024 have been effectively fulfilled, and as of the end of the 2024 fiscal year, there is no need for compensation to the listed company [1].

[Core Performance Forecast Data](index=1&type=section&id=Core%20Performance%20Forecast%20Data) The company forecasts H1 2025 net profit attributable to shareholders and non-recurring net profit to significantly increase H1 2025 Performance Forecast Summary | Metric | H1 2025 Forecast (million CNY) | H1 2024 (Prior Period) (million CNY) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | 790 - 850 | 506.17 | 56.07% - 67.93% | | **Non-recurring Net Profit Attributable to Shareholders** | 760 - 820 | 534.31 | 42.24% - 53.47% | - This performance forecast applies to scenarios where net profit increases by over **50%** year-on-year[2](index=2&type=chunk) - The financial data in this performance forecast is unaudited by a certified public accountant[3](index=3&type=chunk) [Prior Period Performance Review](index=2&type=section&id=Prior%20Period%20Performance%20Review) This section reviews H1 2024 key financial data, including net profit and EPS, providing the baseline for current period growth H1 2024 Key Financial Data | Metric | H1 2024 Amount (million CNY) | | :--- | :--- | | Total Profit | 648.20 | | Net Profit Attributable to Parent Company Owners | 506.17 | | Non-recurring Net Profit Attributable to Parent Company Owners | 534.31 | | Earnings Per Share (CNY) | 0.3047 | [Analysis of Performance Change Reasons](index=2&type=section&id=Analysis%20of%20Performance%20Change%20Reasons) H1 2025 performance growth is primarily driven by optimized internal management and reduced raw material costs - The company achieved tangible results in improving production and operational efficiency through optimized internal management and "Three-Excellence Management" initiatives[5](index=5&type=chunk) - Reduced procurement costs for major raw materials during the reporting period further optimized overall product costs, positively impacting profit growth[5](index=5&type=chunk) [Risk Warning and Other Disclosures](index=3&type=section&id=Risk%20Warning%20and%20Other%20Disclosures) This unaudited performance forecast is a preliminary estimate, with final data subject to the officially disclosed H1 2025 semi-annual report - This performance forecast is a preliminary calculation by the company's finance department based on professional judgment and is unaudited by a certified public accountant[6](index=6&type=chunk) - As of the announcement date, no significant uncertainties affecting the accuracy of this performance forecast have been identified[6](index=6&type=chunk) - Investors are reminded that specific and accurate financial data will be subject to the officially disclosed H1 2025 semi-annual report, and to be aware of investment risks[7](index=7&type=chunk)

证券代码：600866 证券简称：星湖科技 公告编号：临 2025-036 本次解除质押完成后，铁小荣持有公司股份累计质押数量为 0 股； 铁小荣及其一致行动人累计质押数量为 89,351,604 股，占其合计持 股数量的 38.34%，占公司总股本的 5.38%。 2025 年 7 月 10 日，公司收到股东铁小荣《关于所持星湖科技股 份解押的告知函》，获悉其将持有公司的部分股份办理了解除质押手 续，具体情况如下： 一、 本次股份解除质押的具体情况 2023 年 12 月，股东铁小荣将持有公司的 99,826,581 股股份质 押给广东省广新控股集团有限公司（以下简称"广新集团"）作为业 绩承诺的保证，具体内容详见公司于 2023 年 12 月 28 日在上海证券 交易所网站（www.sse.com.cn）披露的《关于持股 5%以上股东部分 股份质押的公告》（公告编号：临 2023-051）。根据信永中和会计师 事务所（特殊普通合伙）出具的《关于宁夏伊品生物科技股份有限公 司 2024 年 度 及 累 积 承 诺 业 绩 实 现 情 况 的 审 核 报 告 》 广东肇庆星湖生物科技股份有限公司 关于持股 5 ...

Investment Rating - The report maintains an "Overweight" rating for the Basic Chemicals and Oil & Gas sectors [5]. Core Insights - The overall price spread in the industry is weak, with the CCPI-oil price spread at approximately 558, below the 30% percentile since 2012, indicating a potential turning point in the industry as supply and demand begin to recover [1][14]. - Capital expenditure growth in the chemical raw materials and products industry has significantly declined, with a year-on-year increase of only 0.4% from January to May 2025, suggesting a self-adjustment phase in the supply side [2][31]. - The domestic PMI for June 2025 is reported at 49.7, indicating a slight recovery in demand, although uncertainties remain regarding tariff policies post-July 9 [2][16]. Summary by Sections Supply Side - The industry capital expenditure growth has dropped to a low level, indicating a potential turning point for supply-side adjustments, with expectations for a recovery starting in the second half of 2025 [2][31]. - The report highlights that the competitive intensity has increased, leading to a significant decline in profitability across most sub-sectors since the second half of 2022 [2][31]. Demand Side - The report notes a recovery in domestic PMI, but uncertainties regarding tariff policies may disrupt future export orders [2][16]. - The demand for chemical products is expected to improve in the medium to long term, supported by domestic economic recovery and growth in demand from regions like Asia, Africa, and Latin America [2][16]. Investment Strategy - The report suggests that the second half of 2025 may see an upward turning point, with a focus on resilient demand and improved supply dynamics [34]. - Specific recommendations include: - Oil & Gas: Favorable long-term prospects for high-dividend companies like China Petroleum [34]. - Bulk Chemicals: Attention on refrigerants and isocyanates, with recommendations for companies like Juhua Co., Luxi Chemical, and Wanhua Chemical [34]. - Downstream Products: Recommendations for companies like Meihua Biological Technology and Xinghuo Technology, anticipating recovery in downstream demand [34]. - Export-driven chemical products: Companies like Senqilin and Sailun Tire are highlighted for their competitive advantages in exports [34]. - High-dividend assets: Companies like Hengli Petrochemical are recommended for their potential to increase dividend payouts [34].

Group 1 - The company held its shareholders' meeting on June 30, 2025, at its headquarters in Zhaoqing, Guangdong Province [1] - A total of 51.8695% of the shares were represented at the meeting, indicating significant shareholder participation [1] - The voting method combined on-site and online voting, which complied with the Company Law and the company's articles of association [1] Group 2 - There was one non-cumulative voting proposal presented at the meeting, which was approved with 99.4849% of the votes in favor [1] - The voting results showed 857,359,051 votes in favor, 4,237,202 votes against, and 201,700 abstentions [1] - The meeting's voting and resolution processes were confirmed to be in accordance with legal and regulatory requirements [2]

北京大成（广州）律师事务所 关于 广东肇庆星湖生物科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 广州市天河区珠江新城珠江东路 6 号周大福金融中心（K11）14 层、15 层 14F，15F，CTF Finance Centre，No.6 Zhujiang East Road， Zhujiang New Town， Guangzhou 510623， China Tel： +86 20-8527 7000 Fax： +86 20-8527 7002 二〇二五年六月 致：广东肇庆星湖生物科技股份有限公司 根据《中华人民共和国证券法》（以下简称《证券法》）、《中华人民共和国公 司法》（以下简称《公司法》）和中国证券监督管理委员会《上市公司股东会规则（2025 修订）》（以下简称《股东会规则》）等法律、法规和其他有关规范性文件的要求， 北京大成（广州）律师事务所（以下简称"本所"）接受广东肇庆星湖生物科技股份 有限公司（以下简称"公司"）的委托，指派律师参加公司 2025 年第一次临时股东大 会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员资 ...

证券代码：600866 证券简称：星湖科技 公告编号：临 2025-034 (一)股东大会召开的时间：2025 年 6 月 30 日 (二)股东大会召开的地点：广东省肇庆市端州区工农北路 67 号公司会议室 广东肇庆星湖生物科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 401 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 861,797,953 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 51.8695 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次大会采取现场记名投票和网络投票相结合的方式表决，符合《公司法》 及公司章程的规定，大会由公司董事长刘立斌先生主持。 ( ...